logo
#

Latest news with #Moximed

GT Medical Technologies Names James Leech Chief Financial and Strategy Officer
GT Medical Technologies Names James Leech Chief Financial and Strategy Officer

Yahoo

time10-06-2025

  • Business
  • Yahoo

GT Medical Technologies Names James Leech Chief Financial and Strategy Officer

Experienced Life Sciences Executive Joins Leadership Team as Company Further Advances Commercialization of GammaTile® TEMPE, Ariz., June 10, 2025 /PRNewswire/ -- GT Medical Technologies, a medical device company with a corporate purpose of improving the lives of patients with brain tumors, today announced that James Leech, a seasoned financial and operational life sciences leader, has joined the company as Chief Financial and Strategy Officer. "We are excited to welcome James as he assumes the Chief Financial and Strategy Officer role at GT Medical Technologies," said Per Langoe, CEO of GT Medical Technologies. "I look forward to collaborating with him to ensure even more doctors and patients have access to GammaTile®. With over 10 years of successful experience leading commercial-stage healthcare-focused companies in an advisory and operational capacity, his expertise on a range of traditional and complex financial and strategic management areas provides us with a substantial opportunity for continued growth and adoption." Mr. Leech will work across the team to accelerate commercial opportunities for GammaTile while spearheading corporate strategy and development, as well as financial and investor management. "I look forward to joining a leadership team that is dedicated to transforming the lives of patients with brain tumors," said Mr. Leech. "GT Medical Technologies is poised for significant growth, and I am thrilled to collaborate with all stakeholders to optimize the company's continued expansion of GammaTile, our FDA-cleared bioresorbable radiotherapy implant for the treatment of brain tumors." Mr. Leech has considerable experience leading businesses from inception through hyper growth phases of their life cycle. He has advised and worked across the life science industry with direct experience in MedTech, healthcare services, and biopharmaceutical sectors across all major therapeutic areas. Previously, Mr. Leech was the Chief Financial and Strategy Officer of Moximed, a commercial-stage orthopedic device company. Prior to Moximed, Mr. Leech was the Chief Business Officer at Palette Life Sciences from the Company's inception through its acquisition by Teleflex, Inc. Mr. Leech started his career in life science investment banking and strategy consulting. He brings significant cross-border experience, having executed transactions and operational initiatives on behalf of and involving companies across the EU and APAC. GammaTile is an innovative form of radiation therapy placed at the time of tumor removal surgery, delivering immediate, targeted radiation to the tumor site when cancer cells are most vulnerable. Unlike conventional approaches, which at their lowest often require a delay between surgery and radiation therapy to allow for wound healing, GammaTile eliminates this treatment gap. By delivering immediate, localized radiation directly at the tumor site, it is designed to maximize the treatment's effectiveness against remaining cancer cells and reduce the risk of regrowth.1 About GT Medical Technologies, Medical Technologies was founded by a dedicated team of brain tumor specialists to address unmet needs in brain tumor treatment. The company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard of care. About GammaTileGammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors. By delivering radiation directly from within—placed into the surgical cavity at the time of tumor removal—GammaTile provides immediate, localized treatment. This approach targets remaining cancer cells when they are most vulnerable to help prevent regrowth, while minimizing radiation exposure to healthy brain tissue. Since its full market launch in the United States in March 2020, GammaTile has been adopted by more than 100 leading centers, underscoring its growing acceptance in both academic and community healthcare settings. For more information, visit and follow @GammaTile on Facebook, Instagram, LinkedIn and X. Media ContactDawn FallonNew Dawn Communications LLCDfallon@ References Garcia MA et al. J Neurooncol. 166:203-212 (2024). View original content to download multimedia: SOURCE GT Medical Technologies

Moximed announces treatment of first subject in trial of knee system
Moximed announces treatment of first subject in trial of knee system

Yahoo

time30-05-2025

  • Business
  • Yahoo

Moximed announces treatment of first subject in trial of knee system

Moximed has announced the treatment of the first subject in the multi-centre MOTION randomised controlled trial (RCT) assessing its MISHA knee system against non-surgical treatment in individuals with medial knee osteoarthritis (OA). This prospective trial is designed to assess the benefits of the MISHA system compared with non-surgical treatment options endorsed by the American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines. These include physical therapy, weight management, physical conditioning, intra-articular injections, assistive devices, and various medications. At least 100 participants will be randomised in the trial, which is currently enrolling at approximately ten sites across the US. Enrolment locations include RUSH University Medical Center, NYU Langone Health, and Scripps Health. The primary endpoint of the study is the improvement in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score. In 2023, the MISHA knee system secured marketing authorisation from the US Food and Drug Administration (FDA). The system claims to have demonstrated superiority to high tibial osteotomy (HTO) in two years after the operation. It is specifically designed for those who have not found relief from previous treatments and are either ineligible for or unwilling to undergo joint replacement surgery. Knee OA is said to arise when the joint's natural shock absorbers, the cartilage and meniscus, fail to cushion it, resulting in chronic pain and restricted activity. Moximed noted that as the first implantable shock absorber for the knee, the MISHA system minimises the load on the joint while walking, potentially alleviating pain, preserving joint function, and delaying the need for replacement surgery. The device is implanted on the medial knee and is engineered to move in harmony with the joint, decreasing 30% of the peak force exerted on the knee during walking. Moximed CEO and president Christopher Gleason said: 'Knee OA patients across the country are looking for an effective and less invasive treatment option without activity restrictions. 'The growing commercial adoption of the MISHA knee system reflects the confidence that physicians and patients have in this breakthrough treatment.' "Moximed announces treatment of first subject in trial of knee system" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store